Alfonso Valle-Muñoz

Alfonso Valle-Muñoz

Auto-generated profile, based on publicly available information

Alfonso Valle-Muñoz

Servicio de Cardiología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2009 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
AVAlfonso Valle-Muñoz
Alfonso Valle-Muñoz
JEJordi Estornell-Erill
Jordi Estornell-Erill
CSCarlos J. Soriano-Navarro
Carlos J. Soriano-Navarro
MNMercedes Nadal-Barange
Mercedes Nadal-Barange
NMNieves Martinez-Alzamora
Nieves Martinez-Alzamora
FRFrancisco Ridocci-Soriano
Francisco Ridocci-Soriano
Aims We evaluated the ability of late gadolinium enhancement (LGE) using cardiovascular magnetic resonance (CMR) to identify acute new-onset heart failure (HF) with left ventricular systolic dysfunction (LVSD), whether or not in relation to underlying coronary artery disease (CAD), in patients with no clinical evidence of associated ischaemic cardiomyopathy. Methods and results Hundred consecutive patients admitted with acute new-onset decompensated HF and EF <40%, with no clinical or electrocardiographic data suggestive of CAD. The patients were classified according to the presence or absence of significant CAD (stenosis ≥70% in at least one major vessel). Twenty-one patients (21%) had significant CAD. Seventy-nine (79%) had no lesions. Eighteen of the 21 patients (85%) with CAD had subendocardial/transmural LGE. In the diagnosis of CAD, LGE has a sensitivity of 85.7% (95% CI, 80–91) and specificity of 92.4% (95% CI, 87–96), respectively, with a negative predictive value of 96% (95% CI, 90–99). It has an area under the receiver operating characteristic curve of 0.906 (95% CI, 0.814–0.998). Conclusion In patients with new-onset HF and LVSD for whom there are no clinical and exploratory data suggestive of ischaemic heart disease, CMR with LGE is an excellent means of ruling out significant CAD and is a valid alternative to angiography.

1 June 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Carlos EscobarCarlos Escobar
Carlos Escobar
XBXavier Borràs
Xavier Borràs
RFRamón Bover Freire
Ramón Bover Freire
Carlos Gonzalez-JuanateyCarlos Gonzalez-Juanatey
Carlos Gonzalez-Juanatey
MMMiren Morillas
Miren Morillas
JDJuan Jose Gomez Doblas
Juan Jose Gomez Doblas
To evaluate the level of agreement between cardiologists regarding the management of oral anticoagulation (OAC) in patients with non-valvular atrial fibrillation (NVAF) in Spain. A two-round Delphi study was performed using an online survey. In round 1, panel members rated their level of agreement with the questionnaire items on a 9-point Likert scale. Item selection was based on acceptance by ≥66.6% of panellists and the agreement of the scientific committee. In round 2, the same panellists evaluated those items that did not meet consensus in round 1. A total of 238 experts participated in round 1; of these, 217 completed the round 2 survey. In round 1, 111 items from 4 dimensions (Thromboembolic and bleeding risk evaluation for treatment decision-making: 18 items; Choice of OAC: 39 items; OAC in specific cardiology situations: 12 items; Patient participation and education: 42 items) were evaluated. Consensus was reached for 92 items (83%). Over 80% of the experts agreed with the use of DOACs as the initial anticoagulant treatment when OAC is indicated. Panellists recommended the use of DOACs in patients at high risk of thromboembolic complications (CHA2DS2-VASc ≥3) (83%), haemorrhages (HAS-BLED ≥3) (89%) and poor quality of anticoagulation control (SAMe-TT2R2 >2) (76%), patients who fail to achieve an optimal therapeutic range after 3 months on VKA treatment (93%), and those who are to undergo cardioversion (80%). Panellists agreed that the efficacy and safety profile of each DOAC (98%), the availability of a specific reversal agent (72%) and patient’s preference (85%) should be considered when prescribing a DOAC. A total of 97 items were ultimately accepted after round 2. This Delphi panel study provides expert-based recommendations that may offer guidance on clinical decision-making for the management of OAC in NVAF. The importance of patient education and involvement has been highlighted.

22 September 2020 in ESC Heart Failure
Verified
Journal Article
Open access
PDF file
RERafael de la Espriella
Rafael de la Espriella
ABAntoni Bayes
Antoni Bayes
HMHerminio Morillas
Herminio Morillas
RBRafael Bravo
Rafael Bravo
VVVerónica Vidal
Verónica Vidal
JNJulio Núñez
Julio Núñez
Aims The aim of this study was to evaluate the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). Methods and results This multicentre observational analysis included 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). The primary endpoint was estimated glomerular filtration rate (eGFR) dynamics across treatment groups. A binary characterization of worsening renal function (WRF)/improved renal function (IRF) was included in the primary endpoint. WRF and IRF were defined as an increase/decrease in serum creatinine ≥ 0.3 mg/dL or GFR ≥ 20%. Changes in quantitative variables were evaluated using joint modelling of survival and longitudinal data (JM). Rates and their treatment differences were determined by Poisson regression. The mean left ventricle ejection fraction and eGFR were 32 ± 6% and 70 ± 28 mL/min/1.73 m2, respectively. At a median follow‐up of 1.01 years (inter‐quartile range 0.71–1.50), 377 outpatient visits were recorded. Although there were differences in GFR trajectories over time within each treatment, they did not achieve statistical significance (omnibus P = 0.154). However, when these differences were contrasted among groups, there was a significant decrease in GFR in Group A as compared with Group B (P = 0.002). The contrast between Groups C and B was not significant (P = 0.430). These differences were also reflected when the rates for WRF and IRF were contrasted among treatments. Conclusions The co‐administration of sacubitril/valsartan and empagliflozin in patients with HFrEF and concomitant T2D appears to be safe in terms of renal function.

1 June 2012 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
JEJordi Estornell-Erill
Jordi Estornell-Erill
BIBegoña Igual-Muñoz
Begoña Igual-Muñoz
JMJose Vicente Monmeneu-Menadas
Jose Vicente Monmeneu-Menadas
CSCarlos Soriano-Navarro
Carlos Soriano-Navarro
AVAlfonso Valle-Muñoz
Alfonso Valle-Muñoz
FRFrancisco Ridocci-Soriano
Francisco Ridocci-Soriano

1 July 2019 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Closed access
HMHerminio Morillas-Climent
Herminio Morillas-Climent
JSJulia Seller-Moya
Julia Seller-Moya
ÁVÁlvaro Vicedo-López
Álvaro Vicedo-López
EGEmilio Galcerá-Jornet
Emilio Galcerá-Jornet
EAEdgard Alania-Torres
Edgard Alania-Torres
AVAlfonso Valle-Muñoz
Alfonso Valle-Muñoz
Aim: To analyze the impact of sacubitril/valsartan on functional class, surrogate parameters and clinical outcomes in clinical practice. Methods: Retrospective study of patients with heart failure and reduced ejection fraction that started treatment with sacubitril/valsartan. Results: 149 patients (70.7 ± 9.6 years) were included. At baseline, 83.9, 15.4 and 0.7% were taking sacubitril/valsartan 24/26, 49/51 and 97/103 mg, respectively. After 316.1 ± 155.9 days, these numbers moved to 38.9, 39.6, 12.8% (8.7% discontinued). Sacubitril/valsartan improved functional class (from 2.3 ± 0.6 to 1.8 ± 0.5; p < 0.001), increased ejection fraction (from 31.2 ± 7.0 to 37.3 ± 10.5%; p < 0.001) and reduced NT-proBNP (from 3884 ± 4871 to 1975.3 ± 3006.6 pg/ml; p = 0.0001). Rates of any event, cardiovascular death and heart failure hospitalization/decompensation were 13.2 events/100 patient-years. Conclusion: Sacubitril/valsartan is effective and safe in routine practice.

1 May 2015 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
OFOscar Fabregat-Andrés
Oscar Fabregat-Andrés
FRFrancisco Ridocci-Soriano
Francisco Ridocci-Soriano
JEJordi Estornell-Erill
Jordi Estornell-Erill
MCMiguel Corbí-Pascual
Miguel Corbí-Pascual
AVAlfonso Valle-Muñoz
Alfonso Valle-Muñoz
MPMaria P. Monsalve Pérez
Maria P. Monsalve Pérez